Assessing the societal impact of acetylcholinesterase inhibitor therapies

Alzheimer Disease and Associated Disorders

Volumn 13, Issue SUPPL. 2, 1999, Pages

  Winblad, Bengt ^a   Wimo, Anders ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

Author keywords

Alzheimer disease; Cost analysis; Donepezil; Metrifonate; Propentofylline; Tacrine

Indexed keywords

CHOLINESTERASE INHIBITOR;

ALZHEIMER DISEASE; CAREGIVER; COST BENEFIT ANALYSIS; COST CONTROL; ECONOMICS; HEALTH CARE COST; HOSPITALIZATION; HUMAN; PHARMACOECONOMICS; PROGNOSIS; QUALITY OF LIFE; REVIEW;

ALZHEIMER DISEASE; CAREGIVERS; CHOLINESTERASE INHIBITORS; COST SAVINGS; COST-BENEFIT ANALYSIS; ECONOMICS, PHARMACEUTICAL; HEALTH CARE COSTS; HOSPITALIZATION; HUMANS; PROGNOSIS; QUALITY OF LIFE; SEVERITY OF ILLNESS INDEX;

EID: 0033218809     PISSN: 08930341     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002093-199911002-00003     Document Type: Article

References (65)

1. Aneshensel CS, Pearlin LI, Mullan JT, et al. Profiles in caregiving: the unexpected career. New York: Academic Press, 1995.
2. Becker RE, Colliver JA, Markwell SJ, et al. Effects of metrifonate on cognitive decline in Alzheimer's disease. A double-blind, placebo-controlled, 6-month study. Alzheimer Dis Assoc Disord 1998;12: 54-7.
3. Bianchetti A, Frisoni GB, Ghisia KM, Trabucchi M. Clinical predictors of the indirect costs of Alzheimer disease. Arch Neurol 1998;55: 130-1.
4. Brodaty H, Peters KE. Cost effectiveness of a training program for dementia carers. Int Psychogeriatr 1991;3:11-22.
5. Clipp EC, Moore MJ. Caregiver time use: an outcome measure in clinical trial research on Alzheimer's disease. Clin Pharmacol Ther 1995;58:228-36.
6. Coen RF, Swanwick GRJ, O'Boyle CA, Coakley D. Behavior disturbance and other predictors of carer burden in Alzheimer's disease. Int J Geriatr Psychiatry 1997;12:331-6.
7. Commonwealth of Australia, Hansard. National Health Amendment Bill (No. 2). Second Reading Speech. Canberra 1987.
8. Cummings JL, Cyrus PA, Bieber F, et al. Metrifonate treatment of the cognitive deficits of Alzheimer's disease. Metrifonate Study Group. Neurology 1998;50:1214-21.
9. Deimling GT, Bass DM. Symptoms of mental impairment among elderly adults and their effects on family caregivers. J Gerontology 1986;41:778-84.
10. Donaldson C, Tarrier N, Burns A. Determinants of carer stress in Alzheimer's disease. Int J Geriatr Psychiatry 1998;13:248-56.
11. Drummond M. Principles of pharmacoeconomics. In: Wimo A, Jönsson B, Karlsson G, Winblad B, eds. Health Economics of Dementia. Chichester: John Wiley & Sons, 1998:141-60.
12. Ebly EM, Parhad IM, Hogan DB, Fung TS. Prevalence and types of dementia in the very old: Results from the Canadian Study of Health and Aging. Neurology 1994;44:1593-600.
13. Ernst RL, Hay JW. The US economic and social costs of Alzheimer's disease revisited. Am J Public Health 1994;84:1261-4.
14. Ernst RL, Hay JW, Fenn C, et al. Cognitive function and the costs of Alzheimer's disease. An exploratory study. Arch Neurol 1997;54: 687-93.
15. Evans D. Estimated prevalence of Alzheimer's disease in the United States. Millbank Q 1990;68:267-89.
16. Fratiglioni L, Viitanen M, Bäckman L, et al. Occurrence of dementia in advanced age: the study design of the Kungsholmen project. Neuroepidemiol 1992;11(Suppl 1):29-36.
17. Fratiglioni L, Forsell Y, Agüero Torres H, Winblad B. Severity of dementia and institutionalization in the elderly: prevalence data from an urban area in Sweden. Neuroepidemiology 1994;13:79-88.
18. Fratiglioni L. Epidemiology. In: Wimo A, Jönsson B, Karlsson G, Winblad B, eds. Health Economics of Dementia. Chichester: John Wiley & Sons, 1998:13-31.
19. Galasko D, Edland SD, Morris JC, et al. The Consortium to Establish a Registry for Alzheimer's disease (CERAD). Part XI. Clinical milestones in patients with Alzheimer's disease followed for over 3 years. Neurology 1995;45:1451-5.
20. Haley WE. The family caregiver's role in Alzheimer's disease. Neurology 1997;48(Suppl 6):S25-S29.
21. Hay JW, Ernst RL. The economic costs of Alzheimer's disease. Am J Public Health 1987;77:1169-75.
22. Henke CJ, Burchmore MJ. The economic impact of tacrine in the treatment of Alzheimer's disease. Clin Ther 1997;19:330-45.
23. Huang L, Cartwright W, Hu T. The economic cost of senile dementia in the United States, 1985. Public Health Rep 1988;103:3-7.
24. Hux MJ, O'Brien BJ, Iskedjian M, et al. Relation between severity of Alzheimer's disease and costs of caring. CMAJ 1998;159:457-65.
25. Karlsson G, Jönsson B, Wimo A, Winblad B. Methodological issues in health economic studies of dementia. In: Wimo A, Jönsson B, Karlsson G, Winblad B, eds. Health Economics of Dementia. Chichester: John Wiley & Sons, 1998:161-9.
26. Katz S, Ford AB, Moskowitz RW, et al. Studies of illness in the aged: the index of ADL, a standardized measure of biological and psychosocial function. JAMA 1963;185:914-9.
27. Kaufer D. Beyond the cholinergic hypothesis: the effect of metrifonate and other cholinesterase inhibitors on neuropsychiatric symptoms in Alzheimer's disease. Dement Geriatr Cogn Disord 1998;9(Suppl 2): 8-14.
28. Kaufer DI, Cummings JL, Christine D, et al. Assessing the impact of neuropsychiatric symptoms in Alzheimer's disease: the Neuropsychiatric Inventory Caregiver Distress Scale. J Am Geriatr Soc 1998a;46:210-5.
29. Kaufer DI, Catt K, Pollock BG, et al. Donepezil in Alzheimer's disease: relative cognitive and neuropsychiatric responses and impact on caregiver distress. Neurology 1998b;50(Suppl 4):A89.
30. Kittner B, Rössner M, Rother M. Clinical trials in dementia with propentofylline. Ann NY Acad Sci 1997;826:307-16.
31. Knapp MJ, Knopman DS, Solomon PR, et al. A 30-week randomized controlled trial of high-dose tacrine in patients with Alzheimer's disease. JAMA 1994;271:985-91.
32. Knopman D, Schneider L, Davis K, et al. Long-term tacrine (Cognex™) treatment: effects on nursing home placement and mortality. Neurology 1996;47(1):166-77.
33. Kurz A. Managing the burden of Alzheimer's disease: a partnership between caregiver and physician. Eur J Neurol 1998;5(Suppl 4): S1-S8.
34. Kyle DR, Drummond MF, White DMD. The Hereford District Department of Mental Health of the Elderly: A Preliminary Evaluation. Community Medicine 1987;9:35-46.
35. Leon J, Neumann PJ, Hermann RC, et al. A cross-sectional study on the health-related quality of life and health service utilization for mild, moderate, and severely impaired Alzheimer's disease patients. Neurology 1998;50:5122.
36. Liebermann MA, Kramer JH. Factors affecting decisions to institutionalize demented elderly. Gerontologist 1991;31:371-4.
37. Lubeck DP, Mazonson PD, Bowe T. The potential impact of tacrine on expenditures for Alzheimer's disease. Med Interface 1994;7: 130-8.
38. Marcusson J, Rother M, Kittner B, et al. A 12-month, randomized, placebo-controlled trial of propentofylline (HWA 285) in patients with dementia according to DSM III-R. Dement Geriatr Cogn Disord 1997;8:320-8.
39. Max W, Webber P, Fox P. Alzheimer's disease: the unpaid burden of caring. J Aging Health 1995;7:179-99.
40. Max W. The cost of Alzheimer's disease. Will drug treatment ease the burden? Pharmacoeconomics 1996;9:5-10.
41. McDaid D. The challenge of dementia: Caring for the carers. Eurohealth 1998;4:11-14.
42. Mittelman MS, Ferris SH, Steinberg G, et al. An intervention that delays institutionalization of Alzheimer's disease patients: treatment of spouse caregivers. Gerontologist 1993;33:730-40.
43. Mittelman MS, Ferris SH, Shulman E, et al. A family intervention to delay nursing home placement of patients with Alzheimer's disease. A randomized controlled trial. JAMA 1996;276:1725-31.
44. Morris JC, Cyrus PA, Orazem J, et al. Metrifonate benefits cognitive, behavioral, and global function in patients with Alzheimer's disease. Neurology 1998;50:1222-30.
45. Neumann PJ, Hermann RC, Kuntz KM, et al. Cost-effectiveness of donepezil in the treatment of mild or moderate Alzheimer's disease. Neurology 1999;52:1138-45.
46. O'Brien B, Goeree R, Hux M, et al. Economic evaluation of donepezil (D) for Alzheimer's disease in Canada. Clin Pharmacol Ther 1998; 63(2):196.
47. Poulshock SW, Deimling GT. Families caring for elders in residence: issues in the measurement of burden. J Gerontol 1984;39:230-9.
48. Rice DP, Fox PJ, Max W, et al. The economic burden of Alzheimer's disease care. Health Aff 1993 (Summer):164-76.
49. Rocca WA, Hofman A, Brayne C, et al. Frequency and distribution of Alzheimer's disease in Europe: A collaborative study of 1980-1990. Prevalence findings. Ann Neurol 1991;30:381-90.
50. Rogers SL, Farlow MR, Doody RS, et al. A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease. Neurology 1998;50;136-45.
51. Skoog I, Nilsson L, Palmertz B, et al. A population-based study of dementia in 85-year olds. N Engl J Med 1993;328:153-8.
52. Small GW, Donohue JA, Brooks RL. An economic evaluation of donepezil in the treatment of Alzheimer's disease. Clin Ther 1998; 20:838-50.
53. Stewart A, Phillips R, Dempsey G. Pharmacotherapy for people with Alzheimer's disease: a Markov-cycle evaluation of five years therapy using donepezil. Int J Geriatr Psychiatry 1998;13:445-53.
54. Teri L. Behavior and caregiver burden: behavioral problems in patients with Alzheimer disease and its association with caregiver distress. Alzheimer Dis Assoc Disord 1997;11(Suppl 4):S35-S38.
55. Victoroff J, Mack WJ, Nielson KA. Psychiatric complications of dementia: impact on caregivers. Dement Geriatr Cogn Disord 1998;9:50-5.
56. Vitaliano PP, Russo J, Young HM, et al. The screen for caregiver burden. Gerontologist 1991;31:76-83.
57. Volicer L, Collard A, Hurley A, et al. Impact of special care unit for patients with advanced Alzheimer's disease on patient's discomfort and costs. J Am Geriatr Soc 1994;42:597-603.
58. Whitlatch CJ. Distress and burden for family caregivers. In: Wimo A, Jönsson B, Karlsson G, Winblad B, eds. Health Economics of Dementia. Chichester: John Wiley & Sons, 1998:123-37.
59. Wilkinson D, Dubois B, Shakespeare A, et al. The effect of metrifonate on the burden to caregivers of patients with Alzheimer's disease. Presented at the 1998 Annual Scientific meeting of the American Geriatrics Society, Seattle, WA, May 1998.
60. Wimo A, Eriksson T, Mattsson B, et al. Cost-utility analysis of group living in dementia care. Int J Technol Assess Health Care 1995;11: 49-65.
61. Wimo A, Karlsson G, Sandman PO, et al. Cost of illness due to dementia in Sweden. Int J Geriatr Psychiatry 1997a;12:857-61.
62. Wimo A, Karlsson G, Nordberg A, Winblad B. Treatment of Alzheimer disease with tacrine: a cost-analysis model. Alzheimer Dis Assoc Disord 1997b;11:191-200.
63. Wimo A, Witthaus E, Rother M, Winblad B. Economic impact of introducing propentofylline for the treatment of dementia in Sweden. Clin Ther 1998a;20:552-66.
64. Wimo A, Wetterholm A-L, Mastey V, Winblad B. Evaluation of the health care resource utilization and caregiver time in anti-dementia drug trials. In: Wimo A, Jönsson B, Karlsson G, Winblad B, eds. Health Economics of Dementia. Chichester: John Wiley & Sons, 1998b:465-99.
65. Zarit SH, Stephens MAP, Townsend A, Greene R. Stress reduction for family caregivers: effects of adult day care use. Paper presented at the Annual conference of the American Psychological Association, August 1996.